Suven Life gets 4 patent approvals for neuro drug

Drug firm Suven Life Sciences today said it has received four product patents in China and Korea for its new chemical entities (NCEs), which could be used for treating various central nervous system disorders.

The four product patents, two from China and two from Korea are valid through 2025 and 2027, Suven Life Sciences said in a filing to BSE.

The company has received approval for molecules that could be used in the treatment of neurodegenerative disorders like Parkinson's, Alzheimer's and Schizophrenia, it added.

Products developed out of these molecules may be out-licensed at various phases of clinical development like Phase I or Phase II, the company said.

Commenting on the development, Suven CEO Venkat Jasti said the company's pipeline of molecules in CNS arena are being developed for cognitive disorders with high unmet medical need and an estimated $30 billion market potential globally.

With these new patents, the company has a total of five patents from China and seven patents from Korea, it added.

Shares of Suven Life Sciences were today trading at Rs 14.70 in the afternoon trade on BSE, up steep 7.69% from its previous close.